Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 18Carcinoma, Renal Cell 8Neuroendocrine Tumors 6Tuberous Sclerosis 3Neoplasm Metastasis 3Kidney Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Seizures 2Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma 2Carcinoid Tumor 2Astrocytoma 2von Hippel-Lindau Disease 1Unilateral Breast Neoplasms 1Tuberous Sclerosis Complex-associated Refractory Seizures 1Tuberous Sclerosis 2 1Thymus Neoplasms 1Stomach Diseases 1Skin Neoplasms 1Renal Cell Cancer Metastatic 1Recurrence 1Prostatic Neoplasms 1Primary Non-metastatic Breast Cancer 1Polycystic Kidney, Autosomal Dominant 1Malignant Carcinoid Syndrome 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1

Interventions

spartalizumab 1sintilimab 1pyrotinib 1pertuzumab 1palbociclib 1Trastuzumab 1Taxes 1Letrozole 1Everolimus 1Capecitabine 1Albumin-Bound Paclitaxel 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2+ Breast Cancer × Everolimus × Clear all
NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

First Affiliated Hospital Xi'an Jiaotong University

Phase 3 Unknown
120 enrolled
Breast

HER2+ Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡